Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

514

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions
InflammationPainCataract
Interventions
DRUG

Loteprednol Etabonate Gel (BID)

One drop of LE gel instilled into the study eye two times per day (BID) for 14 days

DRUG

Loteprednol Etabonate Gel (TID)

One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.

DRUG

Vehicle (BID)

One drop of vehicle instilled into the study eye two times per day (BID) for 14 days

DRUG

Vehicle (TID)

One drop of vehicle instilled into the study eye three times per day (TID) for 14 days

Trial Locations (1)

08807

Bausch & Lomb Incorporated, Bridgewater

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01996839 - Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Biotech Hunter | Biotech Hunter